Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Differing effects of denosumab and alendronate on cortical and trabecular bone

(2013) Roger M. Zebaze et al.   BONE

Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans

(2013) David L Kopperdahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

(2013) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men

(2013) Dana Bliuc et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study

(2012) Michael A. Bolognese et al.   JOURNAL OF CLINICAL DENSITOMETRY

Bisphosphonates for Osteoporosis — Where Do We Go from Here?

(2012) Marcea Whitaker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

(2011) Paul J. Kostenuik et al.   BONE

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

(2011) Matthew Austin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

(2010) H.K. Genant et al.   BONE

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Excess mortality following hip fracture: a systematic epidemiological review

(2009) B. Abrahamsen et al.   OSTEOPOROSIS INTERNATIONAL

Theoretical Implications of the Biomechanical Fracture Threshold

(2008) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH